{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:52:58Z","timestamp":1794243178842,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007398","name":"Strategiske Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["804746"],"award-info":[{"award-number":["804746"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008270","name":"Warwara Larsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008361","name":"Danish Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen Idec Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"NIDA Intramural Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R186-2015-2138"],"award-info":[{"award-number":["R186-2015-2138"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jneuroim.2026.579034","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:03:05Z","timestamp":1784127785000},"page":"579034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Chitinase-1 in cerebrospinal fluid and white matter injury in patients with progressive multiple sclerosis"],"prefix":"10.1016","volume":"420","author":[{"given":"J.","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"H\u00f8jsgaard Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Romme Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ratzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Holm Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Buhelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lundell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Rode","family":"von Essen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Siebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bielekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2026.579034_bb0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fneur.2019.00280","article-title":"Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?","volume":"10","author":"Abdelhak","year":"2019","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2026.579034_bb0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/jnnp-2025-335831","article-title":"Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis","volume":"96","author":"Abdelhak","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2026.579034_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104854","article-title":"NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis","volume":"77","author":"Ammitzb\u00f8ll","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ana.25083","article-title":"Molecular-based diagnosis of multiple sclerosis and its progressive stage","volume":"82","author":"Barbour","year":"2017","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.579034_bb0025","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579034_bb0030","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1038\/s41467-024-49312-y","article-title":"CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis","volume":"15","author":"Beli\u00ebn","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579034_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1352458510382247","article-title":"Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis","volume":"17","author":"B\u00f6rnsen","year":"2011","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.579034_bb0040","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.jneuroim.2026.579034_bb0045","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1474-4422(25)00249-2","article-title":"Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications","volume":"24","author":"Chitnis","year":"2025","journal-title":"Lancet Neurol."},{"issue":"17","key":"10.1016\/j.jneuroim.2026.579034_bb0050","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1212\/WNL.0000000000000361","article-title":"Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial","volume":"82","author":"Christensen","year":"2014","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jneuroim.2026.579034_bb0055","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(14)70101-2","article-title":"Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging","volume":"13","author":"Ciccarelli","year":"2014","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.579034_bb0060","first-page":"1584","article-title":"Patterning chronic active demyelination in slowly expanding\/evolving white matter MS lesions","volume":"41","author":"Elliott","year":"2020","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.579034_bb0065","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1474-4422(18)30451-4","article-title":"Association between pathological and MRI findings in multiple sclerosis","volume":"18","author":"Filippi","year":"2019","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0070","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579034_bb0075","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/brain\/awaa098","article-title":"Neurofilaments: neurobiological foundations for biomarker applications","volume":"143","author":"Gafson","year":"2020","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.nbt.2011.11.016","article-title":"Advances in human proteomics at high scale with the SOMAscan proteomics platform","volume":"29","author":"Gold","year":"2012","journal-title":"New Biotechnol."},{"key":"10.1016\/j.jneuroim.2026.579034_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120320","article-title":"MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis","volume":"439","author":"Hj\u00e6resen","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0090","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001037","article-title":"Dimethyl fumarate treatment in patients with primary progressive multiple sclerosis","volume":"8","author":"H\u00f8jsgaard Chow","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.579034_bb0100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","article-title":"Serum neurofilament light as a biomarker in progressive multiple sclerosis","volume":"95","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063172","article-title":"Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers","volume":"8","author":"Khademi","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579034_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ana.24408","article-title":"Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis","volume":"78","author":"Komori","year":"2015","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579034_bb0115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579034_bb0120","first-page":"3116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.579034_bb0125","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jneuroim.2026.579034_bb0130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.25197","article-title":"Inflammatory intrathecal profiles and cortical damage in multiple sclerosis","volume":"83","author":"Magliozzi","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579034_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102391","article-title":"Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis","volume":"45","author":"Mahler","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.579034_bb0140","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001083","article-title":"CSF levels of CXCL12 and Osteopontin as early markers of primary progressive multiple sclerosis","volume":"8","author":"Marastoni","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.579034_bb0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","article-title":"Cerebrospinal fluid microglial markers in Alzheimer\u2019s disease: elevated Chitotriosidase activity but lack of diagnostic utility","volume":"13","author":"Mattsson","year":"2011","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.jneuroim.2026.579034_bb0150","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3389\/fneur.2019.01232","article-title":"Intrathecal, not systemic inflammation is correlated with multiple sclerosis severity, especially in progressive multiple sclerosis","volume":"10","author":"Milstein","year":"2019","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0155","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/ene.12960","article-title":"Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis","volume":"23","author":"M\u00f8llgaard","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.579034_bb0160","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.579034_bb0165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ana.25691","article-title":"CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity","volume":"87","author":"Oldoni","year":"2020","journal-title":"Ann. Neurol."},{"issue":"10076","key":"10.1016\/j.jneuroim.2026.579034_bb0170","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","article-title":"Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function","volume":"389","author":"Ontaneda","year":"2017","journal-title":"Lancet"},{"issue":"6460","key":"10.1016\/j.jneuroim.2026.579034_bb0175","doi-asserted-by":"crossref","first-page":"eaav7188","DOI":"10.1126\/science.aav7188","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","author":"Patsopoulos","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0180","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000815","article-title":"CSF chitinase 3-like-1 association with disability of primary progressive MS","volume":"7","author":"P\u00e9rez-Miralles","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.jneuroim.2026.579034_bb0185","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1093\/brain\/awn217","article-title":"Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation","volume":"131","author":"Piccio","year":"2008","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579034_bb0190","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.1255","article-title":"Immunopathology of secondary-progressive multiple sclerosis","volume":"50","author":"Prineas","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579034_bb0195","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2025"},{"issue":"10","key":"10.1016\/j.jneuroim.2026.579034_bb0200","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/gerona\/glt022","article-title":"Serum Chitotriosidase, a putative marker of chronically activated macrophages, increases with Normal aging","volume":"68","author":"Ramanathan","year":"2013","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579034_bb0205","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/1352458515605908","article-title":"Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis","volume":"22","author":"Ratzer","year":"2016","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579034_bb0210","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/1352458512466929","article-title":"CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis","volume":"19","author":"Romme Christensen","year":"2013","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579034_bb0215","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000906","article-title":"Chitinase 3\u2013like 1 and neurofilament light chain in CSF and CNS atrophy in MS","volume":"8","author":"Schneider","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579034_bb0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285615615257","article-title":"Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis","volume":"9","author":"Sellebjerg","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jneuroim.2026.579034_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104209","article-title":"Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis","volume":"68","author":"Talbot","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"13","key":"10.1016\/j.jneuroim.2026.579034_bb0230","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1352458513488232","article-title":"Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis","volume":"19","author":"Teunissen","year":"2013","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.579034_bb0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579034_bb0240","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41467-019-08976-7","article-title":"Transcriptional profiling of human microglia reveals grey\u2013white matter heterogeneity and multiple sclerosis-associated changes","volume":"10","author":"van der Poel","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.579034_bb0245","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/13524585231188625","article-title":"Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: an alternative to neurofilament light","volume":"29","author":"Wessels","year":"2023","journal-title":"Mult. Scler."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826001839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826001839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:25:21Z","timestamp":1788873921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"alternative-id":["S0165572826001839"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579034","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chitinase-1 in cerebrospinal fluid and white matter injury in patients with progressive multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"579034"}}